Farmas USA

Acabo de salir del teatro y veo los cierres ... J-o-d-e-r

Los graficos no valen, los estan rompiendo todos!!!

rompiendo líneas y con ganas de más para mañana ¿?

quizás puedan ser buenas entradas o no y quizas no lleguen.

omer y teva

13.1x

sgyp

 2.4x 

adxs

2.9x

nvax 

estoy dentro hace días 1.03 quizás doble posición en 0.9x mañana ya veré, no voy a poder estar muy atento hasta el cierre.

 

 

 

 

SGYP esta aguantando MUY bien.  Se tiene que girar mañana , claro esta.

 

ACHN ha hecho doji donde debia ... hmmmm

GILD

 

Supera expectativas, pero se jode previsión. Se deja + 6%; anda <75. No puedo pegar enlace. Modo móvil

Qué es el limbo? IBB.

 

GILD

Gilead 3rd-quarter profit falls, but beats Wall Street estimates

    By Deena Beasley 
    Oct 26 (Reuters) - Gilead Sciences Inc <GILD.O> reported 
lower third-quarter profits on Thursday as use of its flagship 
hepatitis C drugs continued to wane, but the results beat Wall 
Street estimates due to lower costs. 
    Gilead, which in August paid nearly $12 billion for cancer 
immunotherapy company Kite Pharma, said it earned $2.27 a share 
after one-time items. Wall Street analysts, on average, had 
forecast $2.13 a share, according to Thomson Reuters I/B/E/S. 
    Gilead's quarterly sales of hepatitis C drugs Sovaldi, 
Harvoni, Epclusa and Vosevi totaled $2.2 billion, down from $3.3 
billion a year earlier, and close to the $2.24 billion forecast 
by analysts. The company's antiviral and HIV drug sales rose to 
$3.6 billion from $3.5 billion. 
    Gilead warned earlier this year that sales of its 
high-priced hepatitis C drugs were declining as fewer patients 
were deemed eligible for treatment and competition grew. 
    Overall revenue fell to $6.5 billion from $7.5 billion, 
while analysts had forecast $6.4 billion. Research and 
development costs dropped to $789 million from $1.14 billion. 
    The company said it now expects full-year 2017 hepatitis C 
sales of no more than $9 billion, down from a previous high-end 
estimate of $9.5 billion. 
    Gilead also raised the lower end of its full-year 2017 
product sales outlook to $24.5 billion from a previous estimate 
of $24 billion, but left the upper end unchanged at $25.5 
billion. 
    Net income fell to $2.7 billion from $3.3 billion in the 
year-ago quarter 
 
 (Reporting by Deena Beasley; Editing by Sandra Maler) 
 (([email protected]; 213 955 6746; Reuters 
Messaging: [email protected])) 
 
Keywords: GILEAD RESULTS/ 

 

joerrrrr mas sangre mañana ...

Es Halloween. Mucho susto, pero debería revertirse la tendencia creo yo. Viernes, poco volumen y buen humor. A ver... Creo que funcionará en farmas pequeñas y medianas, cuanto más chicharreras mejor,  independientemente de lo que quieran hacer los índices. Las gordas de GILG y CELG ahora mismo me dan yuyu.